Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer
Irene Yushing Chong, Lauren Aronson, Hanna Bryant, Aditi Gulati, James Campbell, Richard Elliott, Stephen Pettitt, Paul Wilkerson, Maryou B Lambros, Jorge S Reis-Filho, Anisha Ramessur, Michael Davidson, Ian Chau, David Cunningham, Alan Ashworth, Christopher J Lord, Irene Yushing Chong, Lauren Aronson, Hanna Bryant, Aditi Gulati, James Campbell, Richard Elliott, Stephen Pettitt, Paul Wilkerson, Maryou B Lambros, Jorge S Reis-Filho, Anisha Ramessur, Michael Davidson, Ian Chau, David Cunningham, Alan Ashworth, Christopher J Lord
Abstract
Objective: Oesophageal cancer is the seventh most common cause of cancer-related death worldwide. Disease relapse is frequent and treatment options are limited.
Design: To identify new biomarker-defined therapeutic approaches for patients with oesophageal cancer, we integrated the genomic profiles of 17 oesophageal tumour-derived cell lines with drug sensitivity data from small molecule inhibitor profiling, identifying drug sensitivity effects associated with cancer driver gene alterations. We also interrogated recently described RNA interference screen data for these tumour cell lines to identify candidate genetic dependencies or vulnerabilities that could be exploited as therapeutic targets.
Results: By integrating the genomic features of oesophageal tumour cell lines with siRNA and drug screening data, we identified a series of candidate targets in oesophageal cancer, including a sensitivity to inhibition of the kinase BTK in MYC amplified oesophageal tumour cell lines. We found that this genetic dependency could be elicited with the clinical BTK/ERBB2 kinase inhibitor, ibrutinib. In both MYC and ERBB2 amplified tumour cells, ibrutinib downregulated ERK-mediated signal transduction, cMYC Ser-62 phosphorylation and levels of MYC protein, and elicited G1 cell cycle arrest and apoptosis, suggesting that this drug could be used to treat biomarker-selected groups of patients with oesophageal cancer.
Conclusions: BTK represents a novel candidate therapeutic target in oesophageal cancer that can be targeted with ibrutinib. On the basis of this work, a proof-of-concept phase II clinical trial evaluating the efficacy of ibrutinib in patients with MYC and/or ERBB2 amplified advanced oesophageal cancer is currently underway (NCT02884453).
Trial registration number: NCT02884453; Pre-results.
Keywords: Molecular Biology; Oesophageal Cancer.
Conflict of interest statement
Competing interests: IYC has received research funding from Janssen and Pharmacyclics as part of a sponsored research agreement. IC accepts research funding from Janssen-Cilag.
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Figures
References
- Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin 2016;66:7–30. 10.3322/caac.21332
- Rustgi AK, El-Serag HB. Esophageal carcinoma. N Engl J Med 2014;371:2499–509. 10.1056/NEJMra1314530
- Cancer Genome Atlas Research N, Analysis Working Group: Asan U, Agency BCC, Brigham, Women’s H, Broad I et al Integrated genomic characterization of oesophageal carcinoma Nature 2017;541:169–75. 10.1038/nature20805
- Gregson EM, Bornschein J, Fitzgerald RC. Genetic progression of Barrett’s oesophagus to oesophageal adenocarcinoma. Br J Cancer 2016;115:403–10. 10.1038/bjc.2016.219
- Siegel R, Naishadham D, Jemal A, et al. . Cancer statistics, 2012. CA Cancer J Clin 2012;62:10–29. 10.3322/caac.20138
- Shah MA. Update on metastatic gastric and esophageal cancers. J Clin Oncol 2015;33:1760–9. 10.1200/JCO.2014.60.1799
- Cunningham D, Allum WH, Stenning SP, et al. . Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20. 10.1056/NEJMoa055531
- Cunningham D, Starling N, Rao S, et al. . Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36–46. 10.1056/NEJMoa073149
- Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. . Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991–7. 10.1200/JCO.2006.06.8429
- Guimbaud R, Louvet C, Ries P, et al. . Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. J Clin Oncol 2014;32:3520–6. 10.1200/JCO.2013.54.1011
- Al-Batran SE, Hartmann JT, Probst S, et al. . Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008;26:1435–42. 10.1200/JCO.2007.13.9378
- Pozzo C, Barone C, Szanto J, et al. . Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol 2004;15:1773–81. 10.1093/annonc/mdh473
- Bouché O, Raoul JL, Bonnetain F, et al. . Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. J Clin Oncol 2004;22:4319–28. 10.1200/JCO.2004.01.140
- Roth AD, Fazio N, Stupp R, et al. . Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for clinical Cancer research. J Clin Oncol 2007;25:3217–23. 10.1200/JCO.2006.08.0135
- Wilke H, Muro K, Van Cutsem E, et al. . Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014;15:1224–35. 10.1016/S1470-2045(14)70420-6
- Fuchs CS, Tomasek J, Yong CJ, et al. . Ramucirumab Monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383:31–9. 10.1016/S0140-6736(13)61719-5
- Bang YJ, Van Cutsem E, Feyereislova A, et al. . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction Cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687–97. 10.1016/S0140-6736(10)61121-X
- Ross-Innes CS, Becq J, Warren A, et al. . Whole-genome sequencing provides new insights into the clonal architecture of Barrett’s esophagus and esophageal adenocarcinoma. Nat Genet 2015;47:1038–46. 10.1038/ng.3357
- Dulak AM, Stojanov P, Peng S, et al. . Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 2013;45:478–86. 10.1038/ng.2591
- Stachler MD, Taylor-Weiner A, Peng S, et al. . Paired exome analysis of Barrett’s esophagus and adenocarcinoma. Nat Genet 2015;47:1047–55. 10.1038/ng.3343
- Secrier M, Li X, de Silva N, et al. . Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat Genet 2016;48:1131–41. 10.1038/ng.3659
- Sawada G, Niida A, Uchi R, et al. . Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population. Gastroenterology 2016;150:1171–82. 10.1053/j.gastro.2016.01.035
- Song Y, Li L, Ou Y, et al. . Identification of genomic alterations in oesophageal squamous cell Cancer. Nature 2014;509:91–5. 10.1038/nature13176
- Chong IY, Cunningham D, Barber LJ, et al. . The genomic landscape of oesophagogastric junctional adenocarcinoma. J Pathol 2013;231:301–10. 10.1002/path.4247
- Mimura K, Kono K, Hanawa M, et al. . Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer 2005;92:1253–60. 10.1038/sj.bjc.6602499
- Campbell J, Ryan CJ, Brough R, et al. . Large-Scale profiling of kinase dependencies in Cancer cell lines. Cell Rep 2016;14:2490–501. 10.1016/j.celrep.2016.02.023
- Turner N, Lambros MB, Horlings HM, et al. . Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 2010;29:2013–23. 10.1038/onc.2009.489
- Dulak AM, Schumacher SE, van Lieshout J, et al. . Gastrointestinal adenocarcinomas of the esophagus, stomach, and Colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res 2012;72:4383–93. 10.1158/0008-5472.CAN-11-3893
- Dulak AM, Stojanov P, Peng S, et al. . Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 2013;45:478–86. 10.1038/ng.2591
- Agrawal N, Jiao Y, Bettegowda C, et al. . Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov 2012;2:899–905. 10.1158/-12-0189
- Beroukhim R, Mermel CH, Porter D, et al. . The landscape of somatic copy-number alteration across human cancers. Nature 2010;463:899–905. 10.1038/nature08822
- Bandla S, Pennathur A, Luketich JD, et al. . Comparative genomics of esophageal adenocarcinoma and squamous cell carcinoma. Ann Thorac Surg 2012;93:1101–6. 10.1016/j.athoracsur.2012.01.064
- Hu N, Clifford RJ, Yang HH, et al. . Genome wide analysis of DNA copy number neutral loss of heterozygosity (CNNLOH) and its relation to gene expression in esophageal squamous cell carcinoma. BMC Genomics 2010;11:576 10.1186/1471-2164-11-576
- Goh XY, Rees JR, Paterson AL, et al. . Integrative analysis of array-comparative genomic hybridisation and matched gene expression profiling data reveals novel genes with prognostic significance in oesophageal adenocarcinoma. Gut 2011;60:1317–26. 10.1136/gut.2010.234179
- Dutton SJ, Ferry DR, Blazeby JM, et al. . Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncol 2014;15:894–904. 10.1016/S1470-2045(14)70024-5
- Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995;80:179–85. 10.1016/0092-8674(95)90401-8
- Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton’s tyrosine kinase in B cell malignancies. Nat Rev Cancer 2014;14:219–32. 10.1038/nrc3702
- Aoki Y, Isselbacher KJ, Pillai S. Bruton tyrosine kinase is tyrosine phosphorylated and activated in pre-B lymphocytes and receptor-ligated B cells. Proc Natl Acad Sci U S A 1994;91:10606–9. 10.1073/pnas.91.22.10606
- Eifert C, Wang X, Kokabee L, et al. . A novel isoform of the B cell tyrosine kinase BTK protects breast Cancer cells from apoptosis. Genes Chromosomes Cancer 2013;52:961–75. 10.1002/gcc.22091
- Kokabee L, Wang X, Sevinsky CJ, et al. . Bruton’s tyrosine kinase is a potential therapeutic target in prostate cancer. Cancer Biol Ther 2015;16:1604–15. 10.1080/15384047.2015.1078023
- Grassilli E, Pisano F, Cialdella A, et al. . A novel oncogenic BTK isoform is overexpressed in Colon cancers and required for RAS-mediated transformation. Oncogene 2016;35:4368–78. 10.1038/onc.2015.504
- Wang JD, Chen XY, Ji KW, et al. . Targeting btk with ibrutinib inhibit gastric carcinoma cells growth. Am J Transl Res 2016;8:3003–12.
- Byrd JC, Furman RR, Coutre SE, et al. . Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369:32–42. 10.1056/NEJMoa1215637
- Wang ML, Rule S, Martin P, et al. . Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369:507–16. 10.1056/NEJMoa1306220
- Grabinski N, Ewald F. Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells. Invest New Drugs 2014;32:1096–104. 10.1007/s10637-014-0141-2
- Chen J, Kinoshita T, Sukbuntherng J, et al. . Ibrutinib inhibits ERBB receptor tyrosine kinases and HER2-Amplified breast Cancer cell growth. Mol Cancer Ther 2016;15:2835–44. 10.1158/1535-7163.MCT-15-0923
- Sears R, Leone G, DeGregori J, et al. . Ras enhances Myc protein stability. Mol Cell 1999;3:169–79. 10.1016/S1097-2765(00)80308-1
- Sears R, Nuckolls F, Haura E, et al. . Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000;14:2501–14. 10.1101/gad.836800
- Tischler J, Lehner B, Fraser AG. Evolutionary plasticity of genetic interaction networks. Nat Genet 2008;40:390–1. 10.1038/ng.114
- Treon SP, Tripsas CK, Meid K, et al. . Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med 2015;372:1430–40. 10.1056/NEJMoa1501548
- Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 2010;9:57–67. 10.1038/nrd3010
- Pauli C, Hopkins BD, Prandi D, et al. . Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. Cancer Discov 2017;7:462–77. 10.1158/-16-1154
Source: PubMed